Table 4.

Influences of methyldopa and its combinations with individual flavonoids, at the protein level, on selected factors related to in Figure 1. and IL-6) and cardiovascular diseases (TGF-β, VEGF, PIGF, and HIF-1α) in HUVEC.

Group	TNF-α	TGF-β	VEGF	PIGF	HIF-1α	IL-1β	IL-6
	[ng/mL]
control	0.046 ± 0.001	0.150 ± 0.001	0.162 ± 0.001	3.398 ± 0.002	0.017 ± 0.001	0.015 ± 0.001	0.050 ± 0.001
methyldopa	0.040 ± 0.001 *	0.117 ± 0.002 *	0.161 ± 0.001	3.393 ± 0.002	0.025 ± 0.003 *	0.011 ± 0.001	0.057 ± 0.001
apigenin	0.041 ± 0.001 *	0.144 ± 0.001	0.201 ± 0.001 *	3.499 ± 0.002 *	0.022 ± 0.001	0.018 ± 0.001	0.061 ± 0.002 *
Methyldopa + apigenin	0.031 ± 0.002 *,#	0.090 ± 0.002 *,#	0.116 ± 0.002 *,#	3.293 ± 0.003 *,#	0.020 ± 0.001	0.009 ± 0.001 *	0.042 ± 0.001 *,#
baicalein	0.038 ± 0.001 *	0.169 ± 0.001 *	0.155 ± 0.003	3.564 ± 0.002 *	0.025 ± 0.001 *	0.017 ± 0.002	0.069 ± 0.001 *
Methyldopa + baicalein	0.027 ± 0.001 *,#	0.080 ± 0.002 *,#	0.121 ± 0.002 *,#	3.410 ± 0.011	0.019 ± 0.001	0.017 ± 0.001 #	0.037 ± 0.004 *,#
chrysin	0.049 ± 0.001	0.152 ± 0.002	0.165 ± 0.001	3.505 ± 0.003*	0.030 ± 0.001*	0.018 ± 0.001	0.063 ± 0.001*
Methyldopa + chrysin	0.037 ± 0.002 *	0.110 ± 0.001 *,#	0.135 ± 0.002 *,#	3.309 ± 0.011 *,#	0.014 ± 0.001	0.014 ± 0.002	0.040 ± 0.001 *,#
quercetin	0.035 ± 0.002 *	0.096 ± 0.001 *	0.167 ± 0.001	3.204 ± 0.002 *	0.020 ± 0.001	0.014 ± 0.001	0.063 ± 0.002 *
Methyldopa + quercetin	0.032 ± 0.001 *,#	0.081 ± 0.002 *,#	0.046 ± 0.005 *,#	2.805 ± 0.014 *,#	0.014 ± 0.004	0.013 ± 0.003	0.039 ± 0.006 *,#
scutellarin	0.044 ± 0.001	0.154 ± 0.002	0.161 ± 0.001	3.491 ± 0.001 *	0.024 ± 0.001 *	0.020 ± 0.001 *	0.071 ± 0.002 *
Methyldopa + scutellarin	0.030 ± 0.001 *,#	0.130 ± 0.001 *,#	0.093 ± 0.004 *,#	3.344 ± 0.002 *,#	0.030 ± 0.001 *,#	0.014 ± 0.002	0.040 ± 0.001 *,#

Mean ± SD. *—vs. control, p < 0.05. #—vs. methyldopa, p < 0.05.